Showing results (181-190 of 442) with videos related to
Sort By:
Pageof 45
World Journal of Gastroenterology|September 13, 2012
Colometer: a real-time quality feedback system for screening colonoscopyDobromir Filip, Xuexin Gao, Leticia Angulo-Rodríguez, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 20, 2020
Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide AnalysisTarun Chhibba, Leonardo Guizzetti, Cynthia H Seow, et al.United European Gastroenterology Journal|May 23, 2024
Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposureJulian Panés, Geert R D'Haens, Bruce E Sands, et al.Journal of Crohn'S & Colitis|March 24, 2020
Assessment of Endoscopic Healing by Using Advanced Technologies Reflects Histological Healing in Ulcerative ColitisMarietta Iacucci, Rosanna Cannatelli, Xianyong Gui, et al.Inflammatory Bowel Diseases|October 15, 2020
Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and PhysiciansDavid T Rubin, Ailsa Hart, Remo Panaccione, et al.Crohn'S & Colitis 360|August 2, 2026
Bowel urgency in ulcerative colitis is associated with clinical endpoints, health-related quality of life, and biomarkers: data from the etrasimod ELEVATE UC 52 trialMarla C Dubinsky, Erica R Cohen, Peter M Irving, et al.Alimentary Pharmacology & Therapeutics|April 25, 2020
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's diseaseEdward Yang, Nicola Panaccione, Natalie Whitmire, et al.Journal of Crohn'S & Colitis|August 30, 2024
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III TrialsRemo Panaccione, Christopher Ma, Vipul Jairath, et al.Advances in Therapy|August 10, 2024
Comparative Efficacy and Safety of Upadacitinib vs. Vedolizumab, Ustekinumab, and Tofacitinib After Induction and Maintenance for Ulcerative Colitis: Three Matching-Adjusted Indirect ComparisonsWalter Reinisch, Gil Y Melmed, Hiroshi Nakase, et al.Crohn'S & Colitis 360|June 30, 2026
Considerations in reviewing network meta-analyses of heterogeneous clinical trial designs: a methodological review in Crohn's disease and ulcerative colitisChristopher Ma, Eric B Collins, Si-Tien Wang, et al.Pageof 45